Quetiapine augmentation of treatment-resistant depression: a comparison with lithium

References

• Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003;25:2289–304
   PubMed Web of Science ®Google Scholar
• Lam RW, Kennedy SH. Evidence-based strategies for achieving and sustaining full remission in depression: focus on meta analyses. Can J Psychiatry 2004;49(3 Suppl 1):17–26s
   Google Scholar
• Kennedy SH, Eisfeld BS, Meyer JH, Bagby RM. Antidepressants in clinical practice: limitation of assessment methods and drug response. Hum Psychopharmacol 2001;16:105–14
   PubMed Web of Science ®Google Scholar
• McIntyre RS, O’Donovan C. The human cost of not achieving full remission in depression. Can J Psychiatry 2004;49 (3 Suppl 1):10–16s
   Google Scholar
• Greenberg P, Corey-Lisle PK, Birnbaum H, et al. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics 2004;22:363–73
   PubMed Web of Science ®Google Scholar
• Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry 2004;65:341–7
   PubMed Web of Science ®Google Scholar
• Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 2002;63:963–71
   PubMed Web of Science ®Google Scholar
• Petersen T, Gordon JA, Kant A, et al. Treatment resistant depression and axis I co-morbidity. Psychol Med 2001;31:1223–9
   PubMed Web of Science ®Google Scholar
• Canadian Network For Mood And Anxiety Treatments (CANMAT) Depression Work Group; Clinical Guidelines for the Treatment of Depressive Disorders. Can J Psychiatry 2001;46\(Suppl 1):5–90s
   Google Scholar
• De Montigny C, Grunberg F, Mayer A, Deschenes JP. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 1981;138:252–6
   PubMed Web of Science ®Google Scholar
• Bauer M, Forsthoff A, Baethge C, et al. Augmentation therapy in refractory depression-update 2002. Eur Arch Psychiatry Clin Neurosci 2003;253:132–9
   PubMed Web of Science ®Google Scholar
• Mischoulon D, Fava M, Rosenbaum JF. Strategies for augmentation of SSRI treatment: a survey of academic psycho pharmacology practice. Harv Rev Psychiatry 1999;6:322–6
   Google Scholar
• Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1159–72
   PubMed Web of Science ®Google Scholar
• Jones HM, Travis MJ, Mulligan R, et al. In vivo 5-HT2a receptor blockade by quetiapine: an R91150 single photon emission tomography study. Psychopharmacology (Berl) 2001;157:60–6
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Falcone JF, Bauzon D, et al. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol 2001;430:341–9
   PubMed Web of Science ®Google Scholar
• Ichikawa J, Li Z, Dai J, Meltzer HY. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1a receptor agonism. Brain Res 2002;956:349–57
   PubMed Web of Science ®Google Scholar
• Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient’s clinical profile. CNS Spectr 2004;9(10 Suppl 11):6–14
   Google Scholar
• Xu Haiyun, Qing Hong, Lu Wenfu, et al. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett 2002;321:65–8
   PubMed Web of Science ®Google Scholar
• Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med 2004;5:11–25
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 2004;45:104–14
   Google Scholar
• Altar CA, Whitehead RE, Chen R, et al. Effects of electroconvulsive seizures and antidepressant drugs on brain derived neurotrophic factor protein in rat brain. Biol Psychiatry 2003;54:703–9
   PubMed Web of Science ®Google Scholar
• Khouzam HR. Treatment of depressive mood in schizophrenia with the atypical antipsychotic quetiapine. Depress Anxiety 2000;11:80–2
   PubMed Web of Science ®Google Scholar
• Padla D. Quetiapine resolves psychotic depression in an adolescent boy. J Child Adolesc Psychopharmacol 2001;11:207–8
   PubMed Web of Science ®Google Scholar
• Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 2004;65:975–81
   Google Scholar
• Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131–4
   PubMed Web of Science ®Google Scholar
• Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999;60:256–9
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004;65:217–21
   PubMed Web of Science ®Google Scholar
• Sheehan DR, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structural diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59\(Suppl 20):22–33;34–57
   Google Scholar
• Widlocher DJ. Psychomotor retardation: clinical, theoretical, and psychometric aspects. Psychiatr Clin North Am 1983;6:27–40
   PubMed Web of Science ®Google Scholar
• Dantchev N, Widlocher DJ. The measurement of retardation in depression. J Clin Psychiatry 1998;59(Suppl 14):19–25
   PubMed Web of Science ®Google Scholar
• Scandinavian Society of Psychopharmacology Committee of Clinical Investigations. The UKU side effects rating scale; scale for the registration of unwanted effects of psychotropics: manual, English version, October 1986
   Google Scholar
• Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;76(Suppl 334):1–100
   PubMed Web of Science ®Google Scholar
• Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53:649–59
   PubMed Web of Science ®Google Scholar
• Fleck MP, Horwath E. Pharmacologic management of difficult to treat depression in clinical practice. Psychiatr Serv 2005;56:1005–11
   PubMed Web of Science ®Google Scholar
• Quitkin FM, McGrath PJ, Stewart JW, et al. Chronological milestones to guide drug change. When should clinicians switch antidepressants? Arch Gen Psychiatry 1996;53:785–92
   PubMed Web of Science ®Google Scholar
• Lenox RH, McNamara RK, Papke RL, Manji HK. Neurobiology of lithium: an update. J Clin Psychiatry 1998;59(Suppl 6):37–47
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351–60
   PubMed Web of Science ®Google Scholar